Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199

被引：1
|
作者：
Sparano, J. A.
Wang, M.
Martino, S.
Jones, V.
Perez, E.
Saphner, T.
Wolff, A. C.
Sledge, G. W., Jr.
Wood, W. C.
Davidson, N. E.
机构：
[1] Eastern Cooperat Oncol Grp, Brookline, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Southwest Oncol Grp, Ann Arbor, MI USA
[4] Canc & Acute Leukemia Grp B, Chicago, IL USA
[5] North Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer
    Limentani, Steven A.
    Brufsky, Adam M.
    Erban, John K.
    Jahanzeb, Mohammed
    Lewis, Deborah
    CLINICAL BREAST CANCER, 2006, 6 (06) : 511 - 517
  • [42] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
    L. G. Estévez
    P. Sánchez-Rovira
    M. Dómine
    A. León
    I. Calvo
    A. Jaén
    V. Casado
    G. Rubio
    M. Díaz
    C. Miró
    F. Lobo
    E. Carrasco
    M. Casillas
    B. San Antonio
    Clinical and Translational Oncology, 2007, 9 : 317 - 322
  • [43] A phase II study of adjuvant chemotherapy with sequential doxorubicin-cyclophosphamide (AC) and docetaxel followed by radiotherapy in patients with high-risk early breast cancer. A trial of the Pakistan Cancer Research Group
    Khan, Shaharyar
    Shah, Ijaz H.
    Shahid, Abubaker
    Hafeez, Muhammed
    Perveen, Shaheena
    Javed, Abrar A.
    Masood, Ahmed I.
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 67
  • [44] Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: results of a multicenter phase II trial
    Sato, N.
    Iwata, H.
    Masuda, N.
    Nakamura, S.
    Yamamoto, N.
    Kuroi, K.
    Kurosumi, M.
    Tsuda, H.
    Akiyama, F.
    Toi, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 121 - 121
  • [45] TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
    Denise A. Yardley
    Edward R. Arrowsmith
    Brooke R. Daniel
    Janice Eakle
    Adam Brufsky
    David R. Drosick
    Fred Kudrik
    Linda D. Bosserman
    Mark R. Keaton
    Sharon A. Goble
    Jeffrey A. Bubis
    Victor M. Priego
    Kelly Pendergrass
    Yvonne Manalo
    Martin Bury
    Donald S. Gravenor
    Gladys I. Rodriguez
    Roger C. Inhorn
    Robyn R. Young
    William N. Harwin
    Caryn Silver
    John D. Hainsworth
    Howard A. Burris
    Breast Cancer Research and Treatment, 2017, 164 : 649 - 658
  • [46] TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
    Yardley, Denise A.
    Arrowsmith, Edward R.
    Daniel, Brooke R.
    Eakle, Janice
    Brufsky, Adam
    Drosick, David R.
    Kudrik, Fred
    Bosserman, Linda D.
    Keaton, Mark R.
    Goble, Sharon A.
    Bubis, Jeffrey A.
    Priego, Victor M.
    Pendergrass, Kelly
    Manalo, Yvonne
    Bury, Martin
    Gravenor, Donald S.
    Rodriguez, Gladys I.
    Inhorn, Roger C.
    Young, Robyn R.
    Harwin, William N.
    Silver, Caryn
    Hainsworth, John D.
    Burris, Howard A., III
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (03) : 649 - 658
  • [47] Phase II trial of neoadjuvant dose dense chemotherapy for breast cancer with weekly docetaxel and capecitabine, followed by doxorubicin and cyclophosphamide with peg-filgrastim support.
    Birhiray, R. E.
    Harwood, R. M.
    Cudahy, T.
    Beihn, L.
    Miller, J. S.
    Schmidt, R. T.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S154 - S154
  • [48] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Silvia Antolín
    Ramón Mel
    Manuel Ramos
    Andrés García-Palomo
    Concepción Almanza
    Laura de Paz
    Lourdes Calvo
    Elena Álvarez
    Ana González
    Jesús García-Mata
    Clinical and Translational Oncology, 2011, 13 : 686 - 691
  • [49] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Antolin, Silvia
    Mel, Ramon
    Ramos, Manuel
    Garcia-Palomo, Andres
    Almanza, Concepcion
    de Paz, Laura
    Calvo, Lourdes
    Alvarez, Elena
    Gonzalez, Ana
    Garcia-Mata, Jesus
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (09): : 686 - 691
  • [50] Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Rolski, J.
    Chan, A.
    Mackey, J.
    Liu, M.
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T.
    Olsen, S.
    Buyse, M.
    Kiskartalyi, T.
    Landreau, V
    Wilson, V
    Press, M.
    Crown, J.
    CANCER RESEARCH, 2009, 69 (24) : 500S - 500S
12345